APA (7th ed.) Citation

Dummer, R., Biette, K., Gusenleitner, D., Ramesh, R., Lebbe, C., Atkinson, V., . . . Long, G. V. (2020). Effect of first-line spartalizumab + dabrafenib + trametinib on immunosuppressive features detected in peripheral blood and clinical outcome in patients (pts) with advanced BRAF V600–mutant melanoma. Journal of Clinical Oncology, 38, 10034. https://doi.org/10.1200/jco.2020.38.15_suppl.10034

Chicago Style (17th ed.) Citation

Dummer, Reinhard, et al. "Effect of First-line Spartalizumab + Dabrafenib + Trametinib on Immunosuppressive Features Detected in Peripheral Blood and Clinical Outcome in Patients (pts) with Advanced BRAF V600–mutant Melanoma." Journal of Clinical Oncology 38 (2020): 10034. https://doi.org/10.1200/jco.2020.38.15_suppl.10034.

MLA (9th ed.) Citation

Dummer, Reinhard, et al. "Effect of First-line Spartalizumab + Dabrafenib + Trametinib on Immunosuppressive Features Detected in Peripheral Blood and Clinical Outcome in Patients (pts) with Advanced BRAF V600–mutant Melanoma." Journal of Clinical Oncology, vol. 38, 2020, p. 10034, https://doi.org/10.1200/jco.2020.38.15_suppl.10034.